Enzyme-Triggered Microcapsules for Colon-Targeted Delivery of Lacticaseibacillus rhamnosus Improve Metabolic Parameters in an Obese Mouse Model.

IF 4.4 2区生物学 Q1 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

Probiotics and Antimicrobial Proteins Pub Date : 2026-04-30 DOI:10.1007/s12602-026-11035-5

Qikun Cheng, Hengrui Xu, Lijia Shi, Shuyi Li, Shuhua Liu, Wenjing Chen, Dong Ma

{"title":"Enzyme-Triggered Microcapsules for Colon-Targeted Delivery of Lacticaseibacillus rhamnosus Improve Metabolic Parameters in an Obese Mouse Model.","authors":"Qikun Cheng, Hengrui Xu, Lijia Shi, Shuyi Li, Shuhua Liu, Wenjing Chen, Dong Ma","doi":"10.1007/s12602-026-11035-5","DOIUrl":null,"url":null,"abstract":"Obesity is associated with numerous metabolic disorders, and identifying safe and effective strategies for obesity management remains an important research priority. In our previous research, we successfully developed a colon-targeted probiotics oral delivery system, AP2.0, which showed potential for obesity intervention. In this study, Lacticaseibacillus rhamnosus (L. rhamnosus) was encapsulated within AP2.0, and the formulation was tested in a mouse model of obesity. The oral administration of AP2.0@ L. rhamnosus resulted in a 14.6% reduction in body weight gain and a 20% decrease in low-density lipoprotein cholesterol compared to the model group, paralleling the metabolic improvements observed with orlistat in this murine model. 16S rRNA sequencing revealed that oral administration of AP2.0@L. rhamnosus increased the abundance of Streptococcus_acidominimus and Ruminococcaceae, whereas the Orlistat group showed an increase in Bifidobacterium, suggesting distinct gut microbiota modulation profiles associated with weight loss. In conclusion, AP2.0@L. rhamnosus shows promise as a potential intervention for obesity management, although further preclinical and clinical validation is required.","PeriodicalId":20506,"journal":{"name":"Probiotics and Antimicrobial Proteins","volume":" ","pages":""},"PeriodicalIF":4.4000,"publicationDate":"2026-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Probiotics and Antimicrobial Proteins","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.1007/s12602-026-11035-5","RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Obesity is associated with numerous metabolic disorders, and identifying safe and effective strategies for obesity management remains an important research priority. In our previous research, we successfully developed a colon-targeted probiotics oral delivery system, AP_2.0, which showed potential for obesity intervention. In this study, Lacticaseibacillus rhamnosus (L. rhamnosus) was encapsulated within AP_2.0, and the formulation was tested in a mouse model of obesity. The oral administration of AP_2.0@ L. rhamnosus resulted in a 14.6% reduction in body weight gain and a 20% decrease in low-density lipoprotein cholesterol compared to the model group, paralleling the metabolic improvements observed with orlistat in this murine model. 16S rRNA sequencing revealed that oral administration of AP_2.0@L. rhamnosus increased the abundance of Streptococcus_acidominimus and Ruminococcaceae, whereas the Orlistat group showed an increase in Bifidobacterium, suggesting distinct gut microbiota modulation profiles associated with weight loss. In conclusion, AP_2.0@L. rhamnosus shows promise as a potential intervention for obesity management, although further preclinical and clinical validation is required.

查看原文本刊更多论文

酶触发微胶囊用于结肠靶向递送鼠李糖乳杆菌改善肥胖小鼠模型的代谢参数。

肥胖与许多代谢紊乱有关，确定安全有效的肥胖管理策略仍然是一个重要的研究重点。在我们之前的研究中，我们成功开发了一种结肠靶向益生菌口服给药系统AP2.0，显示出干预肥胖的潜力。本研究将鼠李糖乳杆菌（lactoaseibacillus rhamnosus， L. rhamnosus）包封在AP2.0中，并在肥胖小鼠模型中进行了实验。与模型组相比，口服AP2.0@ L.鼠李糖导致体重增加减少14.6%，低密度脂蛋白胆固醇下降20%，与奥利司他在该小鼠模型中观察到的代谢改善相似。16S rRNA测序显示口服AP2.0@L。鼠李糖增加了酸链球菌和瘤胃球菌科的丰度，而奥利司他组则增加了双歧杆菌，这表明肠道微生物群的调节与体重减轻有关。总之，AP2.0@L。鼠李糖有望成为肥胖管理的潜在干预措施，尽管需要进一步的临床前和临床验证。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Probiotics and Antimicrobial Proteins BIOTECHNOLOGY & APPLIED MICROBIOLOGYMICROB-MICROBIOLOGY

CiteScore

11.30

自引率

6.10%

发文量

140

期刊介绍： Probiotics and Antimicrobial Proteins publishes reviews, original articles, letters and short notes and technical/methodological communications aimed at advancing fundamental knowledge and exploration of the applications of probiotics, natural antimicrobial proteins and their derivatives in biomedical, agricultural, veterinary, food, and cosmetic products. The Journal welcomes fundamental research articles and reports on applications of these microorganisms and substances, and encourages structural studies and studies that correlate the structure and functional properties of antimicrobial proteins.